ANNOVIS BIO INC. COMMON STOCK
2.7300
30-July-25 13:30:00
15 minutes delayed
Stocks
+0.0700
+2.63%
Today's range
2.6400 - 2.8700
ISIN
N/A
Source
NYSE
-
Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
09 May 2024 04:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
06 May 2024 04:30:00 By Nasdaq GlobeNewswire
-
29 Apr 2024 07:10:00 By Nasdaq GlobeNewswire
-
02 Apr 2024 04:30:00 By Nasdaq GlobeNewswire
-
01 Apr 2024 05:00:00 By Nasdaq GlobeNewswire
-
20 Mar 2024 04:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
27 Feb 2024 05:00:00 By Nasdaq GlobeNewswire
-
14 Feb 2024 04:30:00 By Nasdaq GlobeNewswire
-
30 Jan 2024 05:00:00 By Nasdaq GlobeNewswire
-
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
24 Jan 2024 05:00:00 By Nasdaq GlobeNewswire
-
Annovis Bio to Participate in the 139th Yale CEO Summit
11 Dec 2023 10:00:00 By Nasdaq GlobeNewswire
-
05 Dec 2023 04:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio Appoints Andrew Walsh as Vice President Finance
01 Dec 2023 04:30:00 By Nasdaq GlobeNewswire
-
27 Nov 2023 04:30:00 By Nasdaq GlobeNewswire
-
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
08 Nov 2023 14:00:00 By Nasdaq GlobeNewswire
-
12 Oct 2023 05:02:38 By Nasdaq GlobeNewswire
-
Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
11 May 2023 04:00:01 By Nasdaq GlobeNewswire
-
Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit
11 Mar 2021 04:05:00 By Nasdaq GlobeNewswire
-
Annovis Bio to Present at the BIO CEO & Investor Digital Conference
16 Feb 2021 03:45:00 By Nasdaq GlobeNewswire